PURPOSE: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. METHODS: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. RESULTS: HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P = .01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. CONCLUSION: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.
PURPOSE: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. METHODS: We examined 235 HIV-1-infectedmen screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. RESULTS:HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P = .01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. CONCLUSION: HGAIN is highly prevalent in HIV-infectedmen. Further studies are needed on treatment and prevention of HGAIN.
Authors: Mark Bower; Tom Powles; Tom Newsom-Davis; Christina Thirlwell; Justin Stebbing; Sundihya Mandalia; Mark Nelson; Brian Gazzard Journal: J Acquir Immune Defic Syndr Date: 2004-12-15 Impact factor: 3.731
Authors: Joel M Palefsky; Elizabeth A Holly; Jimmy T Efirdc; Maria Da Costa; Naomi Jay; J Michael Berry; Teresa M Darragh Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: Peter V Chin-Hong; J Michael Berry; Su-Chun Cheng; Joseph A Catania; Maria Da Costa; Teresa M Darragh; Fred Fishman; Naomi Jay; Lance M Pollack; Joel M Palefsky Journal: Ann Intern Med Date: 2008-09-02 Impact factor: 25.391
Authors: Gypsyamber D'Souza; Dorothy J Wiley; Xiuhong Li; Joan S Chmiel; Joseph B Margolick; Ross D Cranston; Lisa P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2008-08-01 Impact factor: 3.731